Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVCR

NovoCure Ltd

Oct 03 • 03:39PM ET

14.52

Dollar change -0.98
Percentage change -6.35	%

Healthcare • Medical Devices • United Kingdom • NASD

Held by: VTI VB IWM VXF VBK IWO IBB IHI VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	9.89%	Shs Outstand	107.08M	Perf Week	-7.25%
Market Cap	1.57B	Forward P/E	-	EPS next Y	-1.48	Insider Trans	-0.03%	Shs Float	97.51M	Perf Month	-13.08%
Income	-168.70M	PEG	-	EPS next Q	-0.33	Inst Own	85.89%	Short Float	6.26%	Perf Quarter	-13.49%
Sales	549.96M	P/S	2.86	EPS this Y	29.89%	Inst Trans	2.94%	Short Ratio	5.78	Perf Half Y	1.58%
Book/sh	3.35	P/B	4.33	EPS next Y	-8.57%	ROA	-14.23%	Short Interest	6.11M	Perf Year	-5.12%
Cash/sh	8.82	P/C	1.65	EPS next 5Y	-	ROE	-43.40%	52W Range	10.87 - 24.74	Perf YTD	-2.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.97%	ROI	-16.27%	52W High	-41.31%	Beta	0.70
Dividend TTM	-	Quick Ratio	6.22	Sales past 5Y	17.16%	Gross Margin	75.96%	52W Low	33.54%	ATR (14)	1.02
Dividend Ex-Date	-	Current Ratio	6.46	EPS Y/Y TTM	4.62%	Oper. Margin	-32.06%	RSI (14)	33.45	Volatility	5.61% 6.10%
Employees	1453	Debt/Eq	1.87	Sales Y/Y TTM	8.33%	Profit Margin	-30.67%	Recom	2.14	Target Price	25.67
Option/Short	Yes / Yes	LT Debt/Eq	1.87	EPS Q/Q	42.63%	Payout	-	Rel Volume	0.41	Prev Close	15.50
Sales Surprise	10.70%	EPS Surprise	23.06%	Sales Q/Q	19.28%	Earnings	Jul 25 BMO	Avg Volume	1.06M	Price	14.52
SMA20	-13.76%	SMA50	-19.96%	SMA200	-12.96%	Trades		Volume	412,251	Change	-6.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform	$159 → $154

Show Previous Ratings

Oct-01-24 07:00AM	Novocure to Report Third Quarter 2024 Financial Results (Business Wire)
Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)
Sep-06-24 05:19PM	Why NovoCure Stock Dived by 13% This Week (Motley Fool) -6.48%
Sep-03-24 07:00AM	Novocure Announces Planned CEO Transition (Business Wire) -13.84%
Aug-28-24 07:00AM	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Business Wire) +9.61%
09:55AM	Loading…
Aug-16-24 09:55AM	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet (Zacks) -5.34%
Aug-14-24 07:00AM	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Business Wire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
Jul-30-24 09:55AM	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade (Zacks) +12.24%
Jul-25-24 05:30PM	NovoCure (NVCR) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:11AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire) +7.17%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
07:00AM	Loading…
Jul-01-24 07:00AM	Novocure to Report Second Quarter 2024 Financial Results (Business Wire)
Jun-14-24 10:44AM	Cramer's Lightning Round: Novocure, PayPal, AeroVironment (CNBC TV)
Jun-03-24 08:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Business Wire) +8.54%
May-23-24 05:05PM	TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany (Business Wire) -5.86%
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace) +13.01%
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.17%
May-03-24 12:08PM	NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:00AM	NovoCure (NVCR) Q1 2024 Earnings Call Transcript (Motley Fool)
May-02-24 01:19PM	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue (MT Newswires) +11.38%
11:56AM	NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:45AM	NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported (GuruFocus.com)
08:25AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:28AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Business Wire)
07:00AM	Novocure Reports First Quarter 2024 Financial Results (Business Wire)
10:01AM	Loading…
Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-24-24 10:45AM	Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 (Business Wire)
Apr-05-24 07:00AM	Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 (Business Wire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade (Zacks)
07:00AM	Novocure to Report First Quarter 2024 Financial Results (Business Wire)
Mar-30-24 06:34AM	Why NovoCure Stock Soared 18.3% This Week (Motley Fool)
Mar-28-24 11:50AM	Why Novocure Stock Is Jumping Today (Motley Fool) +6.76%
05:01AM	NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 04:08PM	Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish (Investor's Business Daily) +12.01%
09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
09:16AM	Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment (Investor's Business Daily)
07:14AM	UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:12AM	Novocure's device shown to slow cancer progression in the brain in trial (Reuters)
07:05AM	Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-13-24 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Business Wire)
Feb-23-24 11:43AM	NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 12:15PM	NovoCure (NVCR) Q4 2023 Earnings Call Transcript (Motley Fool)
08:25AM	NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:36AM	NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:23AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Business Wire)
Jan-19-24 07:46AM	Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength? (Zacks)
Jan-18-24 02:19PM	Why Is Cancer Focused Novocure Stock Trading Higher Today? (Benzinga) +16.75%
07:00AM	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Business Wire)
Jan-11-24 09:55AM	Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know (Zacks)
Jan-09-24 07:00AM	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Business Wire)
Jan-08-24 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Business Wire) +11.61%
Jan-04-24 04:05PM	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Business Wire)
Dec-27-23 07:00AM	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.20%
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey)
Dec-04-23 04:46PM	The Top and Bottom Stocks of 2023 (Investopedia)
Nov-28-23 10:51AM	Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts (InvestorPlace)
07:30AM	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Business Wire)
Nov-21-23 07:00AM	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-23 09:09AM	11 Best Undervalued UK Stocks To Buy Now (Insider Monkey) +12.48%
Nov-10-23 08:00AM	Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting (Business Wire)
Nov-03-23 06:45AM	Is Novocure Stock a Buy? (Motley Fool)
Oct-30-23 02:04AM	The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-28-23 08:39AM	NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 04:35PM	Why Novocure Stock Was Sick Today (Motley Fool) -7.53%
11:00AM	NovoCure (NVCR) Q3 2023 Earnings Call Transcript (Motley Fool)
08:52AM	NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:24AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-15-23 06:05PM	Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 (Business Wire)
Oct-12-23 08:00AM	Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program (Business Wire) -5.53%
Oct-02-23 07:00AM	Novocure to Report Third Quarter 2023 Financial Results (Business Wire)
Sep-29-23 05:00PM	Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting (Business Wire)
Sep-18-23 11:47AM	Should You Hold NovoCure Limited (NVCR)? (Insider Monkey)
Sep-08-23 04:01PM	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Business Wire)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Sep-04-23 09:30AM	Down 31% in 1 Day, What's Next for NovoCure Stock? (Motley Fool)
Aug-31-23 06:52PM	Why Novocure Stock Fell 24.4% This Week (Motley Fool)
09:55AM	Is NovoCure's Stock Headed for a Free Fall? (Motley Fool)
Aug-29-23 06:31PM	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Business Wire) +8.84% +8.30%
Aug-28-23 05:15PM	Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal (Investopedia) -37.50%
04:08PM	Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails (Investor's Business Daily)
02:19PM	Novocure Plummets 35% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
12:21PM	Why NovoCure Stock Is Crashing Today (Motley Fool)
12:16PM	3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023 (AP Finance)
12:10PM	NovoCure Ltd (NVCR): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:47AM	NovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth Exploration (GuruFocus.com)
09:34AM	Midday movers: 3M, XPeng, Hawaiian Electric Industries and more (Investing.com)
07:27AM	UPDATE 1-Novocure's cancer therapy fails to meet main goal in late-stage trial (Reuters)
07:10AM	Novocure says its ovarian cancer therapy did not meet main goal in late-stage trial (Reuters)
07:00AM	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Financial Officer	Aug 02 '24	Sale	20.14	688	13,857	219,179	Aug 05 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Jun 05 '24	Option Exercise	22.82	124,373	2,838,192	124,373	Jun 07 04:06 PM
VERNON W ANTHONY	Director	Jun 04 '24	Sale	23.89	964	23,033	164,833	Jun 06 05:43 PM
Scannell Timothy J	Director	Jun 04 '24	Sale	23.89	964	23,027	2,964	Jun 06 05:42 PM
LEUNG GABRIEL	Director	Jun 04 '24	Sale	23.89	964	23,025	78,175	Jun 06 05:42 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 01 '24	Sale	16.03	2,107	33,769	252,452	Mar 05 04:09 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 04 '24	Sale	16.01	1,217	19,484	251,235	Mar 05 04:09 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 01 '24	Sale	16.03	1,679	26,909	160,938	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 04 '24	Sale	16.01	840	13,448	160,098	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '24	Sale	16.14	2,078	33,545	162,617	Feb 29 04:38 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Feb 28 '24	Sale	16.14	2,303	37,177	254,559	Feb 29 04:28 PM
Shah Pritesh	Chief Growth Officer	Nov 07 '23	Sale	12.65	382	4,832	124,511	Nov 08 04:22 PM
Cordova Ashley	Chief Financial Officer	Oct 31 '23	Option Exercise	9.58	17,793	170,447	117,443	Nov 02 04:20 PM
Cordova Ashley	Chief Financial Officer	Nov 02 '23	Option Exercise	11.46	175	2,006	117,618	Nov 02 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience